Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy

Journal of Neurology

Volumn 261, Issue 6, 2014, Pages 1227-1233

  Plante Bordeneuve, Violaine ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Amyloidosis; Genetics; Polyneuropathy; Therapeutics; Transthyretin

Indexed keywords

PREALBUMIN;

ARTICLE; AUTONOMIC DYSFUNCTION; CENTRAL NERVOUS SYSTEM; ELECTROPHYSIOLOGY; FAMILIAL AMYLOID POLYNEUROPATHY; FOLLOW UP; GENE THERAPY; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; LIVER TRANSPLANTATION; MISSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY; AMYLOID NEUROPATHIES, FAMILIAL; DISEASE MANAGEMENT; FEMALE; MALE; PORTUGAL;

AMYLOID NEUROPATHIES, FAMILIAL; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; PORTUGAL;

EID: 84903591545     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7373-0     Document Type: Article

References (32)

1. Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408-427
2. Plante-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10(12):1086-1097
3. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 20(8-31):1-18
4. Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411-423
5. Bulawa CE, Connelly S, Devit M et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109(24):9629-9634
6. Rapezzi C, Quarta CC, Obici L et al (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520-528
7. Said G (2003) Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 10(Suppl 1):7-12
8. Lefaucheur JP, Ng Wing Tin S, Kerschen P et al (2013) Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers. J Neurol 260:1497-1503
9. Conceição I, Costa J, Castro J, de Carvalho M (2014) Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy. Muscle Nerve 49(2):181-186
10. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A (1980) Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A (eds) Amyloid and amyloidosis. Excerpta Medica, Amsterdam pp 88-98
11. Ikeda S, Nakazato M, Ando Y et al (2002) Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 58:1001-1007
12. Planté-Bordeneuve V, Ferreira A, Lalu T et al (2007) Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69:693-698
13. Koike H, Morozumi S, Kawagashira Y et al (2009) The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid 16:142-148
14. Ikeda S, Takei Y, Tokuda T, Nakazato M, Ando Y (2003) Clinical and pathological findings of non-Val30Met TTR type familial amyloid polyneuropathy in Japan. Amyloid 10(Suppl 1):39-47
15. Falk RH, Dubrey SW (2010) Amyloid heart disease. Prog Cardiovasc Dis 52:347-361
16. Rapezzi C, Riva L, Quarta CC et al (2008) Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 15(1):40-48
17. Jacobson DR, Pastore RD, Yaghoubian R et al (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336(7):466-473
18. Hellman U, Alarcon F, Lundgren HE et al (2008) Heterogeneity of penetrance in hereditary transthyretin amyloid neuropathy in the Swedish population. Amyloid 15(3):181-186
19. Lemos C, Coelho T, Alves-Ferreira M et al (2014) Overcoming artifact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry 85:326-330
20. Benson M (2013) Liver transplantation and transthyretin amyloidosis. Muscle Nerve 47:157-162
21. Wilczek HE, Larsson M, Ericzon BG (2011) Long term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 18(Suppl. 1):188-190
22. Yamashita T, Ando Y, Okamoto S, Misumi Y et al (2012) Long term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 78:637-643
23. Ihse E, Suhr OB, Hellman U, Westermark P (2011) Variation in amount of wildtype transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) 89:171-180
24. Conceição I, Evangelista T, Castro J et al (2010) Acquired amyloid polyneuropathy in a Portuguese patient after domino liver transplantation. Muscle Nerve 42:836-839
25. Coelho T, Maia LF, da Silva AM et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802-2814
26. Berk JL, Suhr OB, Obici L, Diflunisal Trial Consortium et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310:2658-2667
27. Coelho T, Adams D, Silva A et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819-829
28. Ackermann EJ, Guo S, Booten S et al (2012) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19(Suppl 1):43-44
29. Cardoso I, Merlini G, Saraiva MJ et al (2003) 4′-iodo-4′- Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibrils disrupters. FASEB J 17(8):803-809
30. Obici L, Cortese A, Lozza A et al (2012) Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 19(Suppl 1):34-36
31. Bodin K, Ellmerich S, Kahan MC et al (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468(7320):93-97
32. Planté-Bordeneuve V, Suhr OB, Maurer MS et al (2013) The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 29:77-84